Dr. Reddy’s Shares Trade Higher After Double-Digit Growth In Q4; Buy To Go Long Above Rs 1,220?

Hyderabad, India is home to the headquarters of the multinational pharmaceutical corporation Dr. Reddy's Laboratories Ltd. Dr. Reddy's Laboratories' stock rose to an intraday high of Rs 1,241 after opening higher on the NSE on Tuesday, May 13, at Rs 1,196. The stock was up 1.25% from the previous close at Rs 1,210.60 as of 1:15 p.m. IST, and the price movement is still above short-term moving averages, which is a sign of momentum. Following the company's double-digit growth in Q4FY25, experts advise traders to seek long positions in the stock.

Dr. Reddy's Dividend

The Board of Directors of the company have recommended a final dividend of Rs. 8/- per equity share of Rs. 1/- each for the financial year 2024-25.

The Board "approved convening of 41st Annual General Meeting (AGM) of the members of the Company on Thursday, July 24, 2025. Pursuant to Regulation 42 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 the record date for purpose of determining the members eligible to receive the final dividend for the financial year ended March 31, 2025, has been fixed as July 10, 2025," said Dr. Reddy's in a stock exchange filing.

Dr. Reddy's Q4 Results

In the March 2025 quarter, the company's net profit was Rs. 1,593.30 crore, up 21.64% from Rs. 1,309.80 crore in the March 2024 quarter. In Q4FY25, the company's revenue from operations was Rs 8,528.40 crore, up 19.89% from Q4FY24's Rs 7,113.80 crore. EBITDA increased 24.22% from Rs. 2,028.70 crore in the year-ago quarter to Rs. 2,520.00 crore in the quarter under review. Net sales climbed 16.61% to Rs 32,553.50 crore for the full year FY25, while consolidated net profit improved 1.4% to Rs 5,655.10 crore.

Dr. Reddy's Share Price Target

"Dr. Reddy's is consolidating between ₹1,160-₹1,220 after a recent pullback. The stock has built a base near ₹1,170, acting as strong support. A breakout above ₹1,220 can trigger an up move toward ₹1,260. Price action is holding above short-term moving averages, which is a positive signal. Volume recovery is gradually improving. Traders can look for long positions above ₹1,220 with a stop loss below ₹1,170. Sustained buying pressure will be key for confirmation of a short-term uptrend in this pharmaceutical major," commented Riyank Arora - Technical Analyst - Mehta Equities Limited.

Disclaimer

The recommendations made above are by market analysts and are not advised by either the author, nor Greynium Information Technologies. The author, nor the brokerage firm nor Greynium would be liable for any losses caused as a result of decisions based on this write-up. Goodreturns.in advises users to consult with certified experts before making any investment decision.